Connect with us

Market

Smallcap Company Expects Revenue Growth Thanks to Pharmaceutical Industry; Biodel Inc (NASDAQ:BIOD), Crown Marketing (OTCMKTS:CWNM), Sunshine Biopharma, Inc. (OTCMKTS:SBFM)

Published

on

The pharmaceutical industry saw double-digit growth in 2014 for the first time since the early 2000s, according to the IMS Institute for Healthcare Informatics’s annual report. From ex-manufacturer pricing, drug spending hit $373.9 billion. There is a multitude of elements that played a role in the growth; one of which is a drop in patent expiries. What this did was remove $11.9 billion from industry sales since lower-cost generic drugs acted as surrogates. Also, there was an increase in product launches, which added an extra $20.3 billion. In addition, the rise in pharmaceutical sales, which is up 26.5%, now makes up a third of industry sales.

Crown Marketing (OTCMKTS:CWNM) is a United States company based out of California. The company is focused on mergers and acquisitions that result in significant growth and profits. Crown Marketing primarily seeks out acquisitions from these three industries, all of which have high potential: pharmaceutical, bio-tech and real estate. It seems as though the company has made the most success with the medical side; during the summer, Crown Laboratory, which is a subsidiary of Crown Marketing (OTCMKTS:CWNM), announced that a letter of intent was signed with XinJiang Top Agricultural Public Limited Company in China to export Alfalfa from California to China. Alfalfa is typically used as energy for milk cows or other animals due to its high protein and its pleasant taste to livestock.

According to Crown Laboratory, the venture will be a huge source of revenue. This investment is particularly beneficial because since the population in China is steadily increasing, there is a correspondingly growing need for imported commodities. Crown Laboratory has a chance to expand to the commodity market and officially secured Californian farms that will supply Alfalfa to the China market. Since the time of this press release, CWNM has seen lows of $0.004 and a 125% difference with highs of $0.009. Because Crown Marketing focuses on not just one, but three promising industries, it would not be a surprise to see CWNM grow as the company continues to expand.

Market

Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)

Published

on

By

Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.

REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.

REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.

CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.

Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).

Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.

Continue Reading

Market

ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast

Published

on

By

ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward  to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.

ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.

CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.

MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.

The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.

Continue Reading

Market

Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)

Published

on

By

Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.

CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.

Continue Reading
Advertisement

Trending